Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3915430 | 0.93 | PTPN1 (0.52) | PTPN1LPAR1LPAR2TDP1HSD17B2 | |
| SCHEMBL3913512 | 0.92 | PTPN1 (0.52) | PTPN1LPAR1LPAR2TDP1PPARD | |
| SCHEMBL3920953 | 0.91 | PTPN1 (0.44) | PTPN1LPAR1LPAR2TDP1HSD17B2 | |
| SCHEMBL3911985 | 0.88 | PTPN1 (0.51) | PTPN1 | |
| SCHEMBL3905626 | 0.87 | PTPN1 (0.49) | PTPN1 | |
| SCHEMBL3905224 | 0.85 | PTPN1 (0.47) | PTPN1 | |
| SCHEMBL3908965 | 0.84 | PTPN1 (0.58) | PTPN1 | |
| SCHEMBL3920948 | 0.83 | PTPN1 (0.52) | PTPN1LPAR1LPAR2HSD17B2TSHR | |
| SCHEMBL3909026 | 0.82 | PTPN1 (0.53) | PTPN1LPAR1LPAR2HSD17B2TSHR | |
| SCHEMBL3907456 | 0.82 | PTPN1 (0.68) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521473-B2 | Inhibitors of protein tyrosine phosphatase 1B | WYETH (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | WYETH | 2005-09-15 | — | — | US | disclosed |
| WO-2005081954-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | PTPRO, PTPRS, PTPRM | PTPN1 11/4885LPAR1 3864/4885LPAR2 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.